Peritransplant Ruxolitinib Prevents Acute GVHD in Myelofibrosis Patients Undergoing Allogenic Stem Cell Transplantation

JAK inhibition by Ruxolitinib is approved for treatment of myelofibrosis and showed efficacy in steroid resistant acute and chronic graft-versus-host disease (GVHD)In twelve patients with a median age of 63 years (range 43-71) and myelofibrosis who were treated with ruxolitinib and underwent allogeneic stem cell transplantation (ASCT) ruxolitinib was continued (2 x 5mg) daily until stable engraftment.No graft failure was observed and leukocyte engraftment was achieved after a median of 12 days (range 11 - 18) One patient developed fever of unknown origin after discontinuation of ruxolitinib, otherwise no case of withdrawal syndrome was observed.

Source: Biology of Blood and Marrow Transplantation - May 22, 2018 Category: Hematology Authors: Nicolaus Kr öger, Sharifah Shahnaz Syed Abd Kadir, Tatjana Zabelina, Anita Badbaran, Maximilian Christopeit, Francis Ayuk, Christine Wolschke Source Type: research